NGAL Levels in Down’s Syndrome Patients
Author Information
Author(s): Giada Dogliotti, Emanuela Galliera, Federico Licastro, Elisa Porcellini, Massimiliano M Corsi
Primary Institution: University of Milan
Hypothesis
Can NGAL be used as a marker of inflammatory status for early diagnosis of inflammatory diseases in Down’s syndrome patients?
Conclusion
NGAL levels are significantly higher in Down’s syndrome patients compared to healthy controls and increase with age.
Supporting Evidence
- NGAL levels were significantly higher in adults and elderly Down’s syndrome subjects compared to controls.
- NGAL levels increase with age in Down’s syndrome patients.
- The study suggests NGAL could be a marker for inflammation in Down’s syndrome.
Takeaway
This study found that a protein called NGAL is higher in people with Down’s syndrome, especially as they get older, which might help doctors spot inflammation early.
Methodology
Three groups of Down’s syndrome subjects (children, adults, elderly) were compared to healthy controls using an immuno-enzymatic assay.
Limitations
The study is a pilot and results need confirmation in a larger sample.
Participant Demographics
23 children (2-14 years), 14 adults (20-50 years), 13 elderly (>60 years), and 20 healthy controls (5-60 years).
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website